IONTAS, a provider of antibody discovery and optimization of human monoclonal antibody libraries, has formed an agreement with Teva Pharmaceuticals to apply its technologies and know-how to the optimization of human antibodies for use as biotherapeutics.   IONTAS will initially apply its proprietary technologies to provide Teva with a panel of optimized antibodies against a defined target. Teva will have the option to enter into further optimization programs in the future. The agreement also inc...